Dapagliflozin + Linagliptin

Find more information about this combination medication at the webpages for Dapagliflozin and Linagliptin

English

Brand Name

Linatin D 5mg/10mg Tablet 10s , Linahenz D 10mg/5mg Tablet 10s ... show more

Approved Treatment Indication:

Type 2 Diabetes Mellitus

Listen

This medicine contains a combination of 2 drugs Dapagliflozin and Linagliptin.
Dapagliflozin and Linagliptin are both used to treat the same disease or symptom but work in different ways in the body.
Most doctors will advise making sure that each individual medicine is safe and effective before using a combination form.

Summary

What conditions are Dapagliflozin and Linagliptin used for?
Dapagliflozin and Linagliptin are primarily used to manage type 2 diabetes, which is a condition where the body does not use insulin properly, leading to high blood sugar levels. Dapagliflozin is also used to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular disease, which refers to conditions affecting the heart and blood vessels. Additionally, it helps manage chronic kidney disease, which is a long-term condition where the kidneys do not work as well as they should. Linagliptin is specifically used to improve glycemic control, which means managing blood sugar levels, in type 2 diabetes.
How do Dapagliflozin and Linagliptin work in the body?
Dapagliflozin works by inhibiting the sodium-glucose co-transporter 2 (SGLT2), which is a protein in the kidneys that helps reabsorb glucose back into the blood. By blocking this protein, Dapagliflozin increases glucose excretion through urine, thereby lowering blood sugar levels. Linagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down incretin hormones. These hormones increase insulin secretion, which is the release of insulin from the pancreas, and decrease glucagon levels, which is a hormone that raises blood sugar. Together, these medications provide a comprehensive approach to managing type 2 diabetes by targeting different mechanisms in the body.
What are the usual dosages and routes of administration for Dapagliflozin and Linagliptin?
Dapagliflozin is usually prescribed at a dose of 5 mg or 10 mg taken orally once daily, depending on the specific needs and response of the patient. Linagliptin is typically prescribed at a dose of 5 mg taken orally once daily. Both medications can be taken with or without food, which means they do not require a specific meal schedule. They are often used together to enhance blood sugar control in adults with type 2 diabetes. It is important to take them at the same time each day to maintain consistent blood levels, which helps in managing diabetes effectively.
What are the most commonly observed adverse effects of Dapagliflozin and Linagliptin?
Common side effects of Dapagliflozin include increased urination, which means more frequent trips to the bathroom, urinary tract infections, which are infections in any part of the urinary system, and genital infections. Linagliptin may cause side effects such as a stuffy or runny nose, sore throat, and cough. Both medications can lead to hypoglycemia, which is a condition where blood sugar levels drop too low, especially when used with insulin or sulfonylureas, which are other types of diabetes medications. Patients should be aware of these potential side effects and report any severe or persistent symptoms to their healthcare provider.
What are the important safety warnings and contraindications of Dapagliflozin and Linagliptin?
Dapagliflozin is contraindicated, which means it should not be used, in patients with severe renal impairment, which is a condition where the kidneys do not function well, end-stage renal disease, or those on dialysis. It also carries warnings for ketoacidosis, which is a serious condition where the body produces high levels of blood acids called ketones, and dehydration, which is a condition where the body loses more fluids than it takes in. Linagliptin is contraindicated in patients with a history of hypersensitivity reactions, which are allergic reactions, to the drug. Both medications should be used cautiously in patients with a history of pancreatitis, which is inflammation of the pancreas. Regular monitoring and communication with healthcare providers are essential to manage these risks.

Government Approvals

None

WHO Essential Medicine

Known Teratogen

Pharmaceutical Class

Dipeptidyl Peptidase 4 Inhibitor and Sodium-Glucose Cotransporter 2 Inhibitor

Controlled Drug Substance

Summary

What conditions are Dapagliflozin and Linagliptin used for?
Dapagliflozin and Linagliptin are primarily used to manage type 2 diabetes, which is a condition where the body does not use insulin properly, leading to high blood sugar levels. Dapagliflozin is also used to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular disease, which refers to conditions affecting the heart and blood vessels. Additionally, it helps manage chronic kidney disease, which is a long-term condition where the kidneys do not work as well as they should. Linagliptin is specifically used to improve glycemic control, which means managing blood sugar levels, in type 2 diabetes.
How do Dapagliflozin and Linagliptin work in the body?
Dapagliflozin works by inhibiting the sodium-glucose co-transporter 2 (SGLT2), which is a protein in the kidneys that helps reabsorb glucose back into the blood. By blocking this protein, Dapagliflozin increases glucose excretion through urine, thereby lowering blood sugar levels. Linagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down incretin hormones. These hormones increase insulin secretion, which is the release of insulin from the pancreas, and decrease glucagon levels, which is a hormone that raises blood sugar. Together, these medications provide a comprehensive approach to managing type 2 diabetes by targeting different mechanisms in the body.
What are the usual dosages and routes of administration for Dapagliflozin and Linagliptin?
Dapagliflozin is usually prescribed at a dose of 5 mg or 10 mg taken orally once daily, depending on the specific needs and response of the patient. Linagliptin is typically prescribed at a dose of 5 mg taken orally once daily. Both medications can be taken with or without food, which means they do not require a specific meal schedule. They are often used together to enhance blood sugar control in adults with type 2 diabetes. It is important to take them at the same time each day to maintain consistent blood levels, which helps in managing diabetes effectively.
What are the most commonly observed adverse effects of Dapagliflozin and Linagliptin?
Common side effects of Dapagliflozin include increased urination, which means more frequent trips to the bathroom, urinary tract infections, which are infections in any part of the urinary system, and genital infections. Linagliptin may cause side effects such as a stuffy or runny nose, sore throat, and cough. Both medications can lead to hypoglycemia, which is a condition where blood sugar levels drop too low, especially when used with insulin or sulfonylureas, which are other types of diabetes medications. Patients should be aware of these potential side effects and report any severe or persistent symptoms to their healthcare provider.
What are the important safety warnings and contraindications of Dapagliflozin and Linagliptin?
Dapagliflozin is contraindicated, which means it should not be used, in patients with severe renal impairment, which is a condition where the kidneys do not function well, end-stage renal disease, or those on dialysis. It also carries warnings for ketoacidosis, which is a serious condition where the body produces high levels of blood acids called ketones, and dehydration, which is a condition where the body loses more fluids than it takes in. Linagliptin is contraindicated in patients with a history of hypersensitivity reactions, which are allergic reactions, to the drug. Both medications should be used cautiously in patients with a history of pancreatitis, which is inflammation of the pancreas. Regular monitoring and communication with healthcare providers are essential to manage these risks.

Indications and Purpose

How does combination of Dapagliflozin and Linagliptin work?

Dapagliflozin works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which leads to increased excretion of glucose through urine, thereby lowering blood sugar levels. Linagliptin, on the other hand, inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which increases the levels of incretin hormones. These hormones enhance insulin secretion and decrease glucagon levels, improving blood sugar control. Both medications work together to provide a comprehensive approach to managing type 2 diabetes by targeting different mechanisms in the body.

How effective is combination of Dapagliflozin and Linagliptin?

Clinical trials have demonstrated the effectiveness of Dapagliflozin and Linagliptin in managing type 2 diabetes. Dapagliflozin has been shown to significantly lower HbA1c levels, improve fasting plasma glucose, and reduce the risk of hospitalization for heart failure. Linagliptin effectively lowers HbA1c and improves post-prandial glucose levels by enhancing insulin secretion. Both medications have been studied in various combinations and as monotherapy, consistently showing improvements in glycemic control. Their complementary mechanisms of action provide a robust approach to diabetes management, supported by extensive clinical research.

Directions for Use

What is the usual dose of combination of Dapagliflozin and Linagliptin?

The usual adult daily dose for Dapagliflozin is 5 mg or 10 mg taken orally once daily, depending on the specific needs and response of the patient. Linagliptin is typically prescribed at a dose of 5 mg taken orally once daily. Both medications can be taken with or without food, and they are often used in combination to enhance blood sugar control in adults with type 2 diabetes. The combination of these medications allows for a dual mechanism of action: Dapagliflozin helps remove excess glucose through urine, while Linagliptin increases insulin secretion and decreases glucagon levels.

How does one take combination of Dapagliflozin and Linagliptin?

Dapagliflozin and Linagliptin can be taken with or without food, making them convenient for daily use. It is important to take them at the same time each day to maintain consistent blood levels. Patients should follow their healthcare provider's dietary recommendations, which typically include a balanced diet to help manage diabetes. There are no specific food restrictions associated with these medications, but patients should avoid excessive alcohol consumption, as it can affect blood sugar levels and increase the risk of side effects.

For how long is combination of Dapagliflozin and Linagliptin taken?

Dapagliflozin and Linagliptin are typically used as long-term treatments for managing type 2 diabetes. They are intended for continuous use to maintain blood sugar control, as diabetes is a chronic condition that requires ongoing management. Both medications are taken daily and are part of a comprehensive treatment plan that includes diet and exercise. The duration of use is generally indefinite, as long as the patient continues to benefit from the therapy and does not experience significant side effects.

How long does it take for combination of Dapagliflozin and Linagliptin to work?

Dapagliflozin and Linagliptin, when used together, begin to work shortly after ingestion, but the full effects on blood sugar levels may take a few weeks to become evident. Dapagliflozin works by increasing glucose excretion through urine, which can start within hours of the first dose. Linagliptin increases insulin secretion and decreases glucagon levels, which also starts soon after taking the medication. However, the noticeable improvement in blood sugar control typically requires consistent use over several weeks. Both medications are designed to be taken once daily, and their effects are cumulative, meaning they build up over time with regular use.

Warnings and Precautions

Are there harms and risks from taking combination of Dapagliflozin and Linagliptin?

Common side effects of Dapagliflozin include increased urination, urinary tract infections, and genital infections. Linagliptin may cause side effects such as stuffy or runny nose, sore throat, and cough. Both medications can lead to hypoglycemia, especially when used with insulin or sulfonylureas. Significant adverse effects include the risk of pancreatitis with Linagliptin and dehydration or ketoacidosis with Dapagliflozin. Patients should be aware of these potential side effects and report any severe or persistent symptoms to their healthcare provider.

Can I take combination of Dapagliflozin and Linagliptin with other prescription drugs?

Dapagliflozin may interact with diuretics, increasing the risk of dehydration and hypotension. Linagliptin can interact with strong inducers of CYP3A4 or P-gp, such as rifampin, which may reduce its effectiveness. Both medications can increase the risk of hypoglycemia when used with insulin or insulin secretagogues like sulfonylureas. Patients should inform their healthcare provider of all medications they are taking to manage potential interactions effectively and adjust dosages as necessary.

Can I take combination of Dapagliflozin and Linagliptin if I am pregnant?

Dapagliflozin is not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal kidney development. Linagliptin has not been shown to cause harm in animal studies, but there is limited data on its use in pregnant women. Both medications should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnant women should discuss their treatment options with their healthcare provider to ensure the safest approach to managing diabetes during pregnancy.

Can I take combination of Dapagliflozin and Linagliptin while breastfeeding?

The safety of Dapagliflozin and Linagliptin during lactation is not well established. Dapagliflozin is not recommended during breastfeeding due to the potential risk to the developing kidneys of the infant. Linagliptin's presence in human milk is unknown, but it is present in rat milk, suggesting potential exposure to the infant. Therefore, breastfeeding mothers should consult their healthcare provider to weigh the benefits and risks of continuing these medications while nursing, and alternative treatments may be considered.

Who should avoid taking combination of Dapagliflozin and Linagliptin?

Dapagliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. It also carries warnings for ketoacidosis and dehydration. Linagliptin is contraindicated in patients with a history of hypersensitivity reactions to the drug. Both medications should be used cautiously in patients with a history of pancreatitis. Patients should be aware of the signs of serious side effects, such as severe abdominal pain or difficulty breathing, and seek medical attention if they occur. Regular monitoring and communication with healthcare providers are essential to manage these risks.